Pharmacogenomics and Covid-19 Clinical Import...

Pharmacogenomics and Covid-19 Clinical Importance Exists for Interactions between Repurposed Medications and the Human Genome: A Systematic Review

Author Name : Krishna Baliram Kadam, Dr. Archana Ashok Yelmate, Anjali Ambadas Sabne, Shweta Shivraj Eklinge

ABSTRACT

The corona virus disease 2019 (COVID-19) outbreak is now an active worldwide pandemic. Many medications with unknown efficacy are being tested in clinical settings or used off-label for sympathetic reasons to treat COVID-19 patients. This article examined the possibility of human genome interactions with various effective medications that have been used for the treatment of COVID-19.They provide drug-gene variation combinations that could affect how COVID-19 patients are treated. The most frequently prescribed pharmaceutical variant combinations that have been associated with changes in clinical efficacy are CQ/HCQ (CYP2C8, CYP2D6, ACE2, and HO-1); azithromycin (ABCB1); LPV/r (SLCO1B1, ABCB1, ABCC2, and CYP3A); NVP (ABCC10); oseltamivir (CES1 and ABCB1); remdesivir (CYP2C8, CYP2D6, CYP3A4 and OATP1B1); anakinra (IL-1a); and TCZ; ATV (MDR1 and UGT1A1*28; hyperbilirubinemia; APOA5; dyslipidemia); NVP; and EFV (CYP2B6; depression and suicidal tendencies) are the most frequently used drug variant combinations associated with alterations in side effects.

Keywords: COVID-19, Pharmacogenomics (PGx), Pharmacogenetics